Radiation oncology company Accuray has been granted US Food and Drug Administration (FDA) approval for the Dose Control System, a new feature for the company’s TomoTherapy system.

The TomoTherapy system enables doses to be precisely applied to target structures while sparing healthy tissue.

The Dose Control System ensures a stable output for treatments with a long duration, including total marrow and total body irradiation.

Accuray president and CEO Euan Thomson said that the Dose Control System can improve the TomoTherapy system’s performance.